Regeneron Pharmaceuticals Non-GAAP EPS of $11.49 beats by $1.69, revenue of $2.97B beats by $280M
Regeneron Pharmaceuticals press release  (NASDAQ:REGN): Q1  Non-GAAP EPS of $11.49  beats by $1.69.
Revenue of $2.97B (+17.4% Y/Y)  beats by $280M.
EYLEAÂ U.S.Â net sales increased 13% Y/Y to $1.52B.
DupixentÂ global net sales(c)(recorded by Sanofi) increased 43% Y/Y to $1.81B.
Dupixent approved inÂ EUÂ for children aged 6â11 years with severe asthma.
FDA priority review granted for atopic dermatitis in children aged 6 months to 5 years and eosinophilic esophagitis.
For FY2022, the company expects adjusted gross margin on net product sales of 90% to 92%.